PanTher Therapeutics presents “Phase I Study of PTM-101 as Neoadjuvant Therapy for Borderline Resectable or Locally Advanced Pancreatic Ductal Adenocarcinoma – A Trial in Progress” poster at the American Society for Clinical Oncology 2023 Gastrointestinal Cancers Symposium (ASCO-GI), taking place in San Francisco, Calif., The poster highlights the trial-in-progress for the treatment of borderline resectable or locally advanced pancreatic ductal adenocarcinoma ongoing in Australia. PanTher Therapeutics’ CEO Laura Indolfi and study Principal Investigator John Zalcberg are present to answer any questions.
PanTher Therapeutics Billboard is Live in Times Square, New York, NY
PanTher Therapeutics’ mission of Attacking Cancer at the Source™ is shared from the famous Times Square billboards in New York City November 7-13, 2022. As part of a sponsored campaign with Brex, PanTher displays their mission to the mass of people visiting the major commercial intersection, tourist destination, and entertainment hub that is Times Square.
PanTher’s approach of “Attacking Cancer the Source” featured in the Nature Biopharma Dealmakers publication focused on the oncology landscape
PanTher Therapeutics is targeting solid tumors through direct, localized, and sustained delivery of therapeutic agents. The company’s lead program is in a phase 1 trial, and the company is seeking partners to further develop its platform. Leveraging decades of material science, pharmacology, and cancer biology, PanTher’s innovative approach is truly differentiated from current technologies. In a highly competitive innovative drug discovery market, PanTher’s technology focuses on optimizing the route of administration to unlock a drug’s full potential.